Beigene (NASDAQ:ONC) Posts Earnings Results, Misses Estimates By $0.55 EPS

Beigene (NASDAQ:ONC) released its earnings results on Thursday. The company reported ($1.43) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.88) by ($0.55), Zacks reports. The firm had revenue of $1.13 billion for the quarter, compared to analysts’ expectations of $1.09 billion. Beigene had a negative net margin of 25.94% and a negative return on equity of 25.12%. Beigene updated its FY 2025 guidance to EPS.

Beigene Stock Down 3.2 %

NASDAQ ONC traded down $8.85 on Friday, hitting $269.53. 488,249 shares of the stock were exchanged, compared to its average volume of 408,622. Beigene has a 52-week low of $126.97 and a 52-week high of $287.88. The company has a quick ratio of 1.72, a current ratio of 1.93 and a debt-to-equity ratio of 0.05. The firm has a market capitalization of $26.38 billion, a price-to-earnings ratio of -32.71, a PEG ratio of 7.73 and a beta of 0.63.

Wall Street Analysts Forecast Growth

Separately, Macquarie increased their price objective on shares of Beigene from $259.00 to $313.00 and gave the company an “outperform” rating in a report on Friday.

Insider Transactions at Beigene

In other Beigene news, insider Lai Wang sold 5,000 shares of the business’s stock in a transaction dated Friday, February 21st. The stock was sold at an average price of $257.23, for a total transaction of $1,286,150.00. Following the sale, the insider now owns 920,920 shares in the company, valued at approximately $236,888,251.60. The trade was a 0.54 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Chan Henry Lee sold 1,202 shares of the stock in a transaction on Friday, February 21st. The stock was sold at an average price of $258.04, for a total transaction of $310,164.08. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 58,123 shares of company stock worth $14,081,527. Insiders own 7.43% of the company’s stock.

Beigene Company Profile

BeiGene Ltd. Is a global oncology company, which engages in providing pharmaceutical products. Its medicines include BRUKINSA, TEVIMBRA, and PARTRUVIX. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in George Town, KY.